Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence

[News]

A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) - a biomarker based on the expression levels of seven tumor-specific genes - accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the arom...

More... (http://www.medicalnewstoday.com/releases/266045.php)